Senescent skin cells do more than secrete the well-characterized SASP cocktail of cytokines — they release a distinct class of extracellular vesicles (SA-EVs) with elevated secretion rates, reprogrammed biogenesis, and selectively loaded cargo: proinflammatory microRNAs, mitochondrial DNA, cytokines, EphA2 receptor tyrosine kinase, and noncoding RNAs including tRNAs, lncRNAs, and snoRNAs. This cargo enables senescence to propagate paracrinally to neighboring healthy cells, while simultaneously impairing wound healing, promoting chronic wounds, diabetic ulcers, pathological scarring, and accelerating overall skin aging.
The framing of SA-EVs as a mechanistically distinct arm of the senescence secretome is conceptually important. While SASP has dominated the field for over a decade, growing evidence suggests that vesicle-mediated cargo transfer may be more targeted and harder to pharmacologically intercept than soluble cytokine signaling. The identification of EphA2 as a specific SA-EV cargo protein opens a potential biomarker avenue — serum or skin-surface EV profiling could theoretically stage biological skin age independently of chronological age.
Critically, this is a review-style theoretical paper, not original experimental research — no novel cohort data, animal models, or clinical trial results are presented, limiting its immediate translational weight. Still, its synthesis of senolytic and senomorphic strategies alongside mesenchymal stem cell-derived EV therapeutics and biomaterial delivery platforms offers a useful roadmap. For longevity-focused adults, this signals that topical or systemic EV-targeting approaches may eventually outperform current antioxidant-based skincare paradigms. Incremental framing, but mechanistically clarifying.
